news, page-2

noni you will se 25c soon with a rally to 50 in the near future

PAV-Merial Vaccine (pig viral disease)
The vaccine constructs for the PAV-Merial vaccine
are to be shipped to France for further evaluation.
Merial will test the construct for certain attributes prior
to progressing to animal trials. The timing of the
animal trials is dependent on the availability of trial
facilities. The vaccine cannot be adequately tested
here in Australia for quarantine reasons as the
disease does not occur in Australia.
If successful in animal trials, Imugene would benefit
through licensing the PAV delivery vector for global
sales of this vaccine.
PAV-PRRS Vaccine (porcine respiratory &
respiratory syndrome)
The PAV-PRRS vaccine is ready for testing in pigs.
As with the PAV-Merial vaccine, the PAV-PRRS
vaccine cannot be adequately tested in Australia for
quarantine reasons as the disease does not occur in
Australia. Imugene is in discussions with several
companies to progress these trials in the US.
Granting of the PAV patent in the US is a key factor in
the progression of this product. Imugene is unwilling
to sign long term agreements until the PAV patent is
granted, as the value of the product will significantly
increase with the patent granted.